Argos Therapeutics Inc. (ARGS) Stock Price Up 4.8%
Argos Therapeutics Inc. (NASDAQ:ARGS) shares rose 4.8% on Thursday . The company traded as high as $4.21 and last traded at $4.18, with a volume of 394,533 shares. The stock had previously closed at $3.99.
ARGS has been the topic of a number of recent analyst reports. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Tuesday, May 17th. Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a report on Monday, June 20th. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a report on Friday, June 17th. Eight equities research analysts have rated the stock with a buy rating, Argos Therapeutics has a consensus rating of “Buy” and a consensus target price of $11.50.
The stock’s market cap is $110.78 million. The company’s 50-day moving average price is $5.51 and its 200 day moving average price is $5.84.
Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities research analysts predict that Argos Therapeutics Inc. will post ($1.49) earnings per share for the current year.
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.